Intra-Cellular Therapies Gestion
Gestion contrôle des critères 2/4
Le PDG Intra-Cellular Therapies est Sharon Mates, nommé en May2002, a un mandat de 22.5 ans. La rémunération annuelle totale est $ 10.09M, composée du salaire de 8.8% et des bonus 91.2%, y compris les actions et options de la société. détient directement 1.01% des actions de la société, d'une valeur de $ 91.72M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.1 ans et 10.8 ans.
Informations clés
Sharon Mates
Directeur général
US$10.1m
Rémunération totale
| Pourcentage du salaire du PDG | 8.8% |
| Durée du mandat du directeur général | 22.5yrs |
| Propriété du PDG | 1.0% |
| Durée moyenne d'occupation des postes de direction | 6.1yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 10.8yrs |
Mises à jour récentes de la gestion
Recent updates
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%
Nov 07
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$86m |
| Jun 30 2024 | n/a | n/a | -US$84m |
| Mar 31 2024 | n/a | n/a | -US$111m |
| Dec 31 2023 | US$10m | US$892k | -US$140m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$228m |
| Dec 31 2022 | US$9m | US$849k | -US$256m |
| Sep 30 2022 | n/a | n/a | -US$298m |
| Jun 30 2022 | n/a | n/a | -US$321m |
| Mar 31 2022 | n/a | n/a | -US$304m |
| Dec 31 2021 | US$7m | US$794k | -US$284m |
| Sep 30 2021 | n/a | n/a | -US$259m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$232m |
| Dec 31 2020 | US$5m | US$767k | -US$227m |
| Sep 30 2020 | n/a | n/a | -US$207m |
| Jun 30 2020 | n/a | n/a | -US$187m |
| Mar 31 2020 | n/a | n/a | -US$160m |
| Dec 31 2019 | US$5m | US$745k | -US$148m |
| Sep 30 2019 | n/a | n/a | -US$148m |
| Jun 30 2019 | n/a | n/a | -US$155m |
| Mar 31 2019 | n/a | n/a | -US$154m |
| Dec 31 2018 | US$4m | US$723k | -US$155m |
| Sep 30 2018 | n/a | n/a | -US$145m |
| Jun 30 2018 | n/a | n/a | -US$126m |
| Mar 31 2018 | n/a | n/a | -US$106m |
| Dec 31 2017 | US$5m | US$702k | -US$98m |
Rémunération vs marché: La rémunération totale de Sharon ($USD 10.09M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 7.79M ).
Rémunération et revenus: La rémunération de Sharon a augmenté alors que l'entreprise n'est pas rentable.
PDG
Sharon Mates (71 yo)
22.5yrs
Titularisation
US$10,086,413
Compensation
Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 22.5yrs | US$10.09m | 1.01% $ 91.7m | |
| President | less than a year | US$3.53m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 6.3yrs | US$3.51m | 0.019% $ 1.7m | |
| EVP & Chief Commercial Officer | 6.1yrs | US$3.54m | 0.028% $ 2.5m | |
| Senior VP & Chief Scientific Officer | 9yrs | US$2.13m | pas de données | |
| Vice President of Corporate Communications & Investor Relations | 10.7yrs | US$1.38m | pas de données | |
| Senior VP & Chief Compliance Officer | 5.3yrs | pas de données | pas de données | |
| Senior Vice President | no data | pas de données | pas de données | |
| Senior VP & Head of Regulatory Affairs | 6.2yrs | pas de données | pas de données | |
| Senior VP of Market Access | 5.7yrs | pas de données | pas de données | |
| Senior VP & Head of Clinical Development | 2.6yrs | pas de données | pas de données |
6.1yrs
Durée moyenne de l'emploi
61yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de ITCI est chevronnée et expérimentée (6.1 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$10.09m | 1.01% $ 91.7m | |
| Independent Director | 10.8yrs | US$470.51k | 0.11% $ 10.0m | |
| Lead Independent Director | 10.8yrs | US$507.58k | 0.011% $ 972.1k | |
| Independent Director | 11.3yrs | US$473.34k | 0.039% $ 3.5m | |
| Chairman of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Member of Medical Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 2.6yrs | US$461.30k | 0.0015% $ 134.5k |
10.8yrs
Durée moyenne de l'emploi
71yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la ITCI est chevronné et expérimenté ( 10.8 années d'ancienneté moyenne).